|
KMID : 0988920230210040420
|
|
Intestinal Research
2023 Volume.21 No. 4 p.420 ~ p.432
|
|
|
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
|
|
Kim You-Sun
Edward H. Hurley
Park Yoo-Jeong
Ko Sung-Jin
|
|
|
Abstract
|
|
|
|
Primary sclerosing cholangitis (PSC) is a progressive cholestatic, inflammatory, and fibrotic disease that is strongly associated with inflammatory bowel disease (IBD). PSC-IBD represents a unique disease entity and patients with this disease have an increased risk of malignancy development, such as colorectal cancer and cholangiocarcinoma. The pathogenesis of PSC-IBD involves genetic and environmental factors such as gut dysbiosis and bile acids alteration. However, despite the advancement of disease characteristics, no effective medical therapy has proven to have a significant impact on the prognosis of PSC. The treatment options for patients with PSC-IBD do not differ from those for patients with PSC alone. Potential candidate drugs have been developed based on the pathogenesis of PSC-IBD, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis. In this review, we summarize the current medical treatments for PSC-IBD and the status of new emerging therapeutic agents.
|
|
|
KEYWORD
|
|
|
Inflammatory bowel disease, Primary sclerosing cholangitis, Therapeutics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|